08 July 2021 : Clinical Research
Transurethral Microwave Thermotherapy (TUMT) in the Treatment of Benign Prostatic Hyperplasia: A Preliminary Report
Roger J. Ziętek1BDF, Zbigniew M. Ziętek
123ACE*
DOI: 10.12659/MSM.931597
Med Sci Monit 2021; 27:e931597
Table 5 Prostate-specific antigen concentration at the 3-month follow-up in the transurethral microwave thermotherapy (TUMT) and pharmacologic (control) groups.
| Treatment method | N | PSA (ng/mL) | P | |
|---|---|---|---|---|
| Baseline | After 3 months | |||
| X±SD | X±SD | |||
| TUMT | 840 | 2.9±4.5 | 4.6±5.7 | <0.012 |
| Control | 1040 | 3.0±4.5 | 2.7±3.5 | <0.08 |
| X – mean; SD – standard deviation; PSA – prostate-specific antigen; TUMT – transurethral microwave thermotherapy. statistical significance according to the Mann-Whitney test. | ||||